HER-2/neu gene amplification, represented by the gene/chromosome ratio >2 was uncommon in the NSCLCs (two patients=4%) and even when considering the adenocarcinomas, the fraction of tumours with a maximum HER-2/neu copy number per cell >16 was 8%. Here, ERBB2 is linked to neoplasm.